159 related articles for article (PubMed ID: 25445613)
1. The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial.
Braido F; Melioli G; Candoli P; Cavalot A; Di Gioacchino M; Ferrero V; Incorvaia C; Mereu C; Ridolo E; Rolla G; Rossi O; Savi E; Tubino L; Reggiardo G; Baiardini I; di Marco E; Rinaldi G; Canonica GW; ; Accorsi C; Bossilino C; Bonzano L; DiLizia M; Fedrighini B; Garelli V; Gerace V; Maniscalco S; Massaro I; Messi A; Milanese M; Peveri S; Penno A; Pizzimenti S; Pozzo T; Raie A; Regina S; Sclifò F
Immunol Lett; 2014 Dec; 162(2 Pt B):185-93. PubMed ID: 25445613
[TBL] [Abstract][Full Text] [Related]
2. Prevention of recurrent respiratory tract infections: a literature review of the activity of the bacterial lysate Lantigen B.
Braido F; Melioli G; Nicolini G; Canonica GW
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7756-7767. PubMed ID: 37667954
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of an immune-stimulant(*) constituted by inactivated bacterial bodies in the prophylaxis of infectious episodes of airways: a double blind, placebo-controlled, randomized, multicentre study.
Carlone S; Minenna M; Morlino P; Mosca L; Pasqua F; Pela R; Schino P; Tubaldi A; Tupputi E; De Benedetto F;
Multidiscip Respir Med; 2014; 9(1):58. PubMed ID: 25699178
[TBL] [Abstract][Full Text] [Related]
4. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Lantigen B in the prevention of bacterial respiratory infections.
Pozzi E; Serra C
Monaldi Arch Chest Dis; 2004; 61(1):19-27. PubMed ID: 15366332
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a combination herbal medicinal product containing Tropaeoli majoris herba and Armoraciae rusticanae radix for the prophylactic treatment of patients with respiratory tract diseases: a randomised, prospective, double-blind, placebo-controlled phase III trial.
Fintelmann V; Albrecht U; Schmitz G; Schnitker J
Curr Med Res Opin; 2012 Nov; 28(11):1799-807. PubMed ID: 23083066
[TBL] [Abstract][Full Text] [Related]
7. Open comparative, randomized controlled clinical study of a new immunostimulating bacterial lysate in the prophylaxis of upper respiratory tract infections.
Macchi A; Vecchia LD
Arzneimittelforschung; 2005; 55(5):276-81. PubMed ID: 15960427
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections.
Esposito S; Bianchini S; Bosis S; Tagliabue C; Coro I; Argentiero A; Principi N
J Transl Med; 2019 Aug; 17(1):284. PubMed ID: 31443716
[TBL] [Abstract][Full Text] [Related]
9. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial.
Stokholm J; Chawes BL; Vissing NH; Bjarnadóttir E; Pedersen TM; Vinding RK; Schoos AM; Wolsk HM; Thorsteinsdóttir S; Hallas HW; Arianto L; Schjørring S; Krogfelt KA; Fischer TK; Pipper CB; Bønnelykke K; Bisgaard H
Lancet Respir Med; 2016 Jan; 4(1):19-26. PubMed ID: 26704020
[TBL] [Abstract][Full Text] [Related]
10. Oropharyngeal Probiotic ENT-K12 as an Effective Dietary Intervention for Children With Recurrent Respiratory Tract Infections During Cold Season.
Guo H; Xiang X; Lin X; Wang Q; Qin S; Lu X; Xu J; Fang Y; Liu Y; Cui J; Li Z
Front Nutr; 2022; 9():900448. PubMed ID: 35634421
[TBL] [Abstract][Full Text] [Related]
11. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial.
Jara-Pérez JV; Berber A
Clin Ther; 2000 Jun; 22(6):748-59. PubMed ID: 10929921
[TBL] [Abstract][Full Text] [Related]
12. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study.
Rudenko N; Dorofeyev A
Arzneimittelforschung; 2005; 55(7):420-7. PubMed ID: 16080282
[TBL] [Abstract][Full Text] [Related]
13. Exploring association between gastrointestinal heat retention syndrome and recurrent respiratory tract infections in children: a prospective cohort study.
Dong F; Yu H; Ma J; Wu L; Liu T; Lv G; Zhen J; Li X; Lewith G; Gu X
BMC Complement Altern Med; 2016 Feb; 16():82. PubMed ID: 26921252
[TBL] [Abstract][Full Text] [Related]
14. A preventive measure for otitis media in children with upper respiratory tract infections.
Mora R; Barbieri M; Passali GC; Sovatzis A; Mora F; Cordone MP
Int J Pediatr Otorhinolaryngol; 2002 Apr; 63(2):111-8. PubMed ID: 11955602
[TBL] [Abstract][Full Text] [Related]
15. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double-blind clinical trial.
Tricarico D; Varricchio A; D'Ambrosio S; Ascione E; Motta G
Arzneimittelforschung; 2004; 54(1):57-63. PubMed ID: 14979610
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of bacterial lysate OM-85 in the treatment of uncomplicated acute respiratory infections: a double-blind, placebo-controlled, multicenter, randomized trial].
Kalyuzhin OV; Gorelov AV; Malyavin AG; Zaytsev AA; Esaulenko EV; Novak KE; Bykov AS
Ter Arkh; 2023 Nov; 95(10):850-858. PubMed ID: 38159017
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children.
Fiocchi A; Omboni S; Mora R; Macchi A; Nespoli L; Arrigoni S; Guastini L; Castelnuovo P; Graziani D; Marcassa S
Allergy Asthma Proc; 2012; 33(2):197-204. PubMed ID: 22525398
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections.
Koatz AM; Coe NA; Cicerán A; Alter AJ
Lung; 2016 Aug; 194(4):687-97. PubMed ID: 27117798
[TBL] [Abstract][Full Text] [Related]
19. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of Yupingfeng granules in children with recurrent respiratory tract infection: A randomized clinical trial.
Xu B; Li X; Hu S; Bao Y; Chen F; Chen Z; Du Y; Liu E; Liu Y; Mou Q; Su B; Wang B; Xu J; Xu G; Yang Q; Gao L; Liu X; Li L; Ma R; Shen K
Pediatr Investig; 2022 Jun; 6(2):75-84. PubMed ID: 35774519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
